Lantern Pharma (LTRN) to Release Quarterly Earnings on Thursday

Lantern Pharma (NASDAQ:LTRN) will announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Lantern Pharma (NASDAQ:LTRN) last issued its earnings results on Thursday, August 8th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.09. During the same quarter in the previous year, the business earned ($0.44) EPS. On average, analysts expect Lantern Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Lantern Pharma Stock Performance

Shares of NASDAQ LTRN opened at $3.27 on Wednesday. Lantern Pharma has a 52-week low of $2.74 and a 52-week high of $11.99. The firm has a market capitalization of $35.22 million, a price-to-earnings ratio of -1.98 and a beta of 1.58. The stock has a 50 day moving average price of $3.66 and a 200 day moving average price of $4.55.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.